Abstract：Objective To explore the clinical effect of Alprostadil in the treatment of patients with coronary atherosclerotic heart disease. Methods Fifty patients with coronary atherosclerotic heart disease treated in our hospital from October 2016 to October 2018 were selected as the research subjects, they were divided into the observation group (25 cases) and the control group (25 cases) according to the random number table method. The observation group was treated with Alprostadil, the control group was treated with Nitroglycerin. The clinical treatment effects, cardiac function-related indicators, and blood lipid levels before and after treatment were compared between the two groups. Results The total effective rate of treatment in the observation group was higher than that in the control group, the difference was statistically significant (P＜0.05). The cardiac output (SV) of the observation group was higher than that of the control group, the heart rate (HR) was lower than that of the control group, the differences were statistically significant(P＜0.05). Before treatment, there were no significant differences in serum total cholesterol (TC), triacylglycerol (TG),low density lipoprotein cholesterol (LDL-C), and high density lipoprotein cholesterol (HDL-C) between the two groups(P＞0.05). After treatment, the levels of TC, TG, and LDL-C in the two groups were lower than those of before treatment, the levels of HDL-C was higher than that of before treatment, the levels of TC, TG, LDL-C in the observation group were lower than those in the control group, the levels of HDL-C was higher than that in the control group, the differences were statistically significant (P ＜0.05). Conclusion The use of Alprostadil in patients with coronary atherosclerotic heart disease can improve the treatment effect, improve cardiac function indicators and blood lipid levels, which is worthy of clinical application.
江涛；廖英坚. 前列地尔治疗冠状动脉粥样硬化性心脏病患者的临床效果[J]. 中国当代医药, 2020, 27(6): 76-78.
JIANG Tao LIAO Ying-jian. Clinical effect of Alprostadil in the treatment of patients with coronary atherosclerotic heart disease. 中国当代医药, 2020, 27(6): 76-78.
Krcutz RP，Nystrom P，Krcutz Y，et al.Inhibition of platclct agagrcgation by prostaglandin EL in diabctic paticnts during therapy with elopdogrel and aspirin [J].Platelets，2013，24（2）：145-150.
Ye Z，Lu H，Guo W，et a l.The effect of alprostadilon preventing contrast -induced nephropathy for pereutancous coronary intervention in diabetic patients：a systematic review and meta-analysis[J].Medicine，2016，95（46）：5306.
京公网安备 11010502046607号